Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plummeted 6.13% on October 31, 2024, following the company's third-quarter financial results and a strategic shift in its business focus.
The biopharmaceutical company reported quarterly revenue of $3.74 million, missing analyst consensus estimates of $10.36 million by a significant 63.9%. This represented a 20.9% year-over-year decline, sending the stock into a tailspin as investors reacted to the disappointing top-line performance.
While Kymera beat earnings estimates, reporting a loss of $0.82 per share compared to the expected $0.84, the company's strategic pivot also weighed on investor sentiment. Kymera unveiled plans to shift its focus and resources from oncology to its expanding immunology pipeline, stating that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. The company also selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。